Peptide Based Infection Therapeutics Market by Product Type, Distribution Channel and Region – Size, Share, Trends, and Forecast 2019 – 2026

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Excessive and inappropriate use of antibiotics is creating antibiotic resistance among affected population at present. Therefore, urge of developing novel therapies in fighting infections is increasing. A novel peptide-based therapies for treating infections has offered various advantages in terms of stability, safety, tolerance, possesses selective nature, effective with broad spectrum of activities and mechanisms. They also protect the host from pathogenic microbes, for which these are referred as host defense peptides.

Get FREE Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/2185

Peptide-based Infection Therapeutics Market – Drivers

Increasing number of pipeline drugs is expected to drive peptide-based infection therapeutics market. For instance, in September 2018, BioAegis Therapeutics Inc. started clinical trials for Phase 1b/2a study of recombinant plasma gelsolin (rhu-pGSN) in community-acquired pneumonia (CAP), in Australasia and has observed reduced morbidity and mortality in over 20 infectious and non-infectious disease animal models.

Furthermore, LA Jolla Pharmaceutical Company is undergoing phase II clinical trials for LJPC-501, and is expected to complete study in April 2023. This drug can be used for treating Septic Shock.

Peptide-based Infection Therapeutics Market – Restraint

High cost of alternative techniques in manufacturing of peptide drugs to avoid peptide degradation is expected to hamper growth of the market. For instance, according to an article published in Biomolecule 2017, utilization of techniques such as Liposomes, PEGylation, need to develop for effective peptide drug delivery have increased the overall cost of therapy and thus restraint the growth of the market.

Peptide-based Infection Therapeutics Market – Regional Analysis

On the basis of region, the peptide-based infection therapeutics market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America expected to show higher market attractiveness and domination over other regions due to new advancements in treatment such as peptide vaccines, and presence of large number of peptide manufacturing companies. In 2014-2015, AmbioPharm, Inc., a company of U.S., manufactures peptide-based antifungals with better efficacy. This company has also expanded its manufacturing units in the U.S. and China to cater to the demands.

Furthermore, high prevalence of infectious diseases is also expected to drive growth of market in U.S. For instance, according to the World Health Organization (WHO) 2016 statistics, in the U.S., number of new tuberculosis cases were 9,272 and number of new salmonella cases were 53,850.

Browse Research Report At: https://www.coherentmarketinsights.com/ongoing-insight/peptide-based-infection-therapeutics-market-2185

Peptide-based Infection Therapeutics Market – Competitive Landscape

The key players operating in this market include Vertex Pharmaceuticals Incorporated, Merck & Co., Inc. Parchem Fine & Specialty Chemicals, AmbioPharm Inc., CoredentPharma International, GenScript, Sun Pharmaceutical Industries Ltd., Bharat Biotech, and Dr. Reddy’s Laboratories Ltd.

Peptide-based Infection Therapeutics Market – Taxonomy

By Drug

• Telaprevir
• Boceprevir

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Africa
• Middle East

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.